UNIGE document Scientific Article
previous document  unige:89753  next document
add to browser collection

Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial

Courvoisier, D. S.
Published in Journal of Dental Research. 2016, vol. 95, no. 3, p. 349-355
Abstract Accumulating evidence suggests that periodontal infections may have an impact on systemic health. In patients with untreated periodontitis, very high values for several inflammatory markers in serum are expressed simultaneously. We investigated to what extent these peak values change after nonsurgical and surgical periodontal treatment, with adjunctive antibiotics administered during the first or the second treatment phase. In a single-center, randomized, placebo-controlled, and double-masked clinical trial, 80 patients with chronic or aggressive periodontitis were randomized into 2 treatment groups: group A, receiving systemic amoxicillin and metronidazole during the first, nonsurgical phase of periodontal therapy (phase 1), and group B, receiving the antibiotics during the second, surgical phase (phase 2). Serum samples were obtained at baseline (BL), 3 mo after phase 1 (M3), and 6 and 12 mo after phase 2 (M6, M12). Samples were evaluated for 15 cytokines and 9 acute-phase proteins using the Bio-Plex bead array multianalyte detection system. For each analyte, peak values were defined as greater than mean +2 SD of measurements found in 40 periodontally healthy persons. Sixty-six patients showed a peak value of at least 1 analyte at BL. At M12, the number of these patients was only 36 (P = 0.0002). This decrease was stronger in group A (BL: 35, M12: 19, P = 0.0009) than in group B (BL: 31, M12: 17, P = 0.14). Twenty patients displayed peak values of at least 4 biomarkers at BL. The nonsurgical therapy delivered in the first phase reduced most of these peaks (group A, BL: 9, M3: 4, P = 0.17; group B, BL: 11, M3: 2, P = 0.01), irrespective of adjunctive antibiotics. The reductions obtained at M3 were maintained until M12 in both groups. Initial, nonsurgical periodontal therapy reduced the incidence of peak levels of inflammatory markers. Antibiotics and further surgical therapy did not enhance the effect (Clinicaltrials.gov NCT02197260).
Keywords Acute-Phase Proteins/analysis Adult Aged Aggressive Periodontitis/blood/*drug therapy/surgery Amoxicillin/therapeutic use Anti-Bacterial Agents/*therapeutic use Biomarkers/blood Calcitonin/blood Chronic Periodontitis/blood/*drug therapy/surgery Combined Modality Therapy Cytokines/blood Double-Blind Method Female Ferritins/blood Follow-Up Studies Haptoglobins/analysis Humans Inflammation Mediators/*blood Interleukin 1 Receptor Antagonist Protein/blood Interleukin-10/blood Male Metronidazole/therapeutic use Middle Aged Periodontal Debridement/methods Placebos Protein Precursors/blood Serum Amyloid P-Component/analysis acute phase proteins antimicrobials clinical research cytokines periodontal therapy serum
Full text
Article (Published version) (386 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Research group Groupe Mombelli Andréa (médecine dentaire) (242)
(ISO format)
GIANNOPOULOU, Catherine et al. Systemic Biomarkers in 2-Phase Antibiotic Periodontal Treatment: A Randomized Clinical Trial. In: Journal of Dental Research, 2016, vol. 95, n° 3, p. 349-355. doi: 10.1177/0022034515618949 https://archive-ouverte.unige.ch/unige:89753

221 hits

0 download


Deposited on : 2016-12-02

Export document
Format :
Citation style :